{"id":689618,"date":"2024-02-28T09:52:01","date_gmt":"2024-02-28T09:52:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=689618"},"modified":"2024-02-28T09:52:01","modified_gmt":"2024-02-28T09:52:01","slug":"anticd20-antibody-pipeline-outlook-report-2024","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/anticd20-antibody-pipeline-outlook-report-2024_689618.html","title":{"rendered":"Anti-CD20 Antibody Pipeline Outlook Report 2024"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1709117414.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Anti-CD20 Antibody Pipeline Outlook Report 2024\" src=\"https:\/\/www.abnewswire.com\/uploads\/1709117414.png\" alt=\"Anti-CD20 Antibody Pipeline Outlook Report 2024\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, &ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/anti-cd20-antibody-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\"><strong>Anti-CD20 Antibody Pipeline Insight 2024<\/strong><\/a>&rdquo; report provides comprehensive insights about 20+ Anti-CD20 Antibody companies and 20+ pipeline drugs in Anti-CD20 Antibody pipeline landscape. It covers the Anti-CD20 Antibody pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Anti-CD20 Antibody pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Anti-CD20 Antibody Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>DelveInsight&rsquo;s Anti-CD20 Antibody pipeline report depicts a robust space with 20+&nbsp;Anti-CD20 Antibody companies working to develop 20+ pipeline therapies for Anti-CD20 Antibody treatment.<\/li>\n<li>The leading companies working in the Anti-CD20 Antibody market include&nbsp;<em>TG Therapeutics, Roche, Genmab\/ Novartis, Biocad, Regeneron Pharmaceuticals, IGM Biosciences, Genentech, MENTRIK Biotech, Xencorm, KindredBio, Boehringer Ingelheim, Bioxpress therapeutics, 3SBio, Sinocelltech, Alopexx Oncology, Pfizer, Protheragen, Biogen Idec\/Genentech, BioThera solutions, and others<\/em>.<\/li>\n<li>Promising Anti-CD20 Antibody Pipeline Therapies in the various stages of development include&nbsp;<em>Zanubrutinib, Rituximab, Lenalidomide, Obinutuzumab, Ofatumumab, Cyclophosphamide, Doxorubicin, Acalabrutinib, Obinutuzumab and Pixantrone, and others.<\/em><\/li>\n<li>On July 2023, University of Washington announced a study of Phase 2 Clinical Trials for Obinutuzumab, Rituximab, and Pembrolizumab. This phase II trial studies how well pembrolizumab with rituximab or obinutuzumab work in treating patients with follicular lymphoma or diffuse large B cell lymphoma that has come back (recurrent) or does not respond to treatment (refractory).<\/li>\n<li>On July 2023, Cho Pharma Inc. announced a study of Phase 1 &amp; 2 Clinical Trials for CHO-H01. This is a 2-part study. Part 1\/Phase 1 of the study will be conducted to determine the safety and tolerability of CHO-H01 in subjects with relapsed\/refractory CD20+ non-Hodgkin&#8217;s lymphoma. It will also determine maximum tolerated dose (MTD) and recommended phase II dose (RP2D).<\/li>\n<li>On August 2023, BeiGene announced a study of Phase 3 Clinical Trials for Zanubrutinib, Rituximab, Lenalidomide, and Obinutuzumab. The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed\/refractory (R\/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET\/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R^2 in participants with R\/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Request a sample and discover the recent advances in Anti-CD20 Antibody Treatment Drugs @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/anti-cd20-antibody-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Anti-CD20 Antibody Pipeline Report<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">The Anti-CD20 Antibody pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Anti-CD20 Antibody drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Anti-CD20 Antibody clinical trial landscape.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Anti-CD20 Antibody Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">CD20 is a 33- to 37-kDa non-glycosylated phosphoprotein expressed on the surface of mature undifferentiated B-cells. Expression starts at the pre&ndash;B-cell stage, and persists until terminal differentiation into plasma cells.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Find out more about Anti-CD20 Antibody Treatment Landscape @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/anti-cd20-antibody-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Drugs for Anti-CD20 Antibody Treatment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Anti-CD20 Antibody Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Ublituximab: TG therapeutics<\/li>\n<li>Glofitamab: Roche<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Anti-CD20 Antibody Pipeline Therapeutics Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">The Anti-CD20 Antibody pipeline report proffers an integral view of the Anti-CD20 Antibody emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about the emerging Anti-CD20 Antibody Pipeline Therapies @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/anti-cd20-antibody-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Anti-CD20 Antibody Clinical Trials Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Anti-CD20 Antibody Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<li>Anti-CD20 Antibody Companies-&nbsp;<em>TG Therapeutics, Roche, Genmab\/ Novartis, Biocad, Regeneron Pharmaceuticals, IGM Biosciences, Genentech, MENTRIK Biotech, Xencorm, KindredBio, Boehringer Ingelheim, Bioxpress therapeutics, 3SBio, Sinocelltech, Alopexx Oncology, Pfizer, Protheragen, Biogen Idec\/Genentech, BioThera solutions, and others.<\/em><\/li>\n<li>Anti-CD20 Antibody Pipeline Therapies-&nbsp;<em>Zanubrutinib, Rituximab, Lenalidomide, Obinutuzumab, Ofatumumab, Cyclophosphamide, Doxorubicin, Acalabrutinib, Obinutuzumab and Pixantrone, and others.<\/em><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Dive deep into rich insights for new drugs for Anti-CD20 Antibody Treatment, Visit @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/anti-cd20-antibody-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Anti-CD20 Antibody Market Drivers and Barriers, and Future Perspective<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>Anti-CD20 Antibody: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Anti-CD20 Antibody &ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>In-depth Commercial Assessment<\/li>\n<li>Anti-CD20 Antibody Collaboration Deals<\/li>\n<li>Late Stage Products (Preregistration)<\/li>\n<li>Ublituximab: TG therapeutics<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>Odronextamab: Regeneron Pharmaceuticals<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Early stage products (Phase I)<\/li>\n<li>IGM 2323: IGM Biosciences<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Inactive Products<\/li>\n<li>Anti-CD20 Antibody Key Companies<\/li>\n<li>Anti-CD20 Antibody Key Products<\/li>\n<li>Anti-CD20 Antibody- Unmet Needs<\/li>\n<li>Anti-CD20 Antibody- Market Drivers and Barriers<\/li>\n<li>Anti-CD20 Antibody- Future Perspectives and Conclusion<\/li>\n<li>Anti-CD20 Antibody Analyst Views<\/li>\n<li>Anti-CD20 Antibody Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>&nbsp;&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=anticd20-antibody-pipeline-outlook-report-2024\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9650213330<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/primary-research-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/primary-research-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/primary-research-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=anticd20-antibody-pipeline-outlook-report-2024\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s, &ldquo;Anti-CD20 Antibody Pipeline Insight 2024&rdquo; report provides comprehensive insights about 20+ Anti-CD20 Antibody companies and 20+ pipeline drugs in Anti-CD20 Antibody pipeline landscape. It covers the Anti-CD20 Antibody pipeline drug profiles, including clinical and nonclinical stage products. It also &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/anticd20-antibody-pipeline-outlook-report-2024_689618.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,413],"tags":[],"class_list":["post-689618","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/689618","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=689618"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/689618\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=689618"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=689618"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=689618"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}